PriceTargets.com logo

Trevena - TRVN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $1.50
  • Forecasted Upside: 114.29%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.70 As of 03/30/2023 01:00 AM ET
▼ -0.03 (-4.11%)

This chart shows the closing price for TRVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Trevena Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRVN

Analyst Price Target is $1.50
▲ +114.29% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Trevena in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 114.29% upside from the last price of $0.70.

This chart shows the closing price for TRVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Trevena. This rating has held steady since October 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2022HC WainwrightLower Target$1.50Low
5/12/2022HC WainwrightLower Target$5.00 ➝ $3.50Medium
10/1/2021OppenheimerReiterated RatingHoldHigh
9/7/2021JMP SecuritiesReiterated RatingBuy$6.00High
3/15/2021OppenheimerInitiated CoverageMarket PerformMedium
9/14/2020GuggenheimInitiated CoverageBuy$5.00High
8/27/2020Cantor FitzgeraldInitiated CoverageOverweight$5.00High
8/11/2020HC WainwrightBoost TargetBuy$4.00 ➝ $5.00Low
6/16/2020HC WainwrightReiterated RatingBuyHigh
3/13/2020HC WainwrightReiterated RatingBuy$3.50High
11/5/2019HC WainwrightReiterated RatingBuy$3.50High
6/24/2019HC WainwrightSet TargetBuy$4.00Low
5/31/2019HC WainwrightInitiated CoverageNeutral ➝ Buy$3.50High
3/14/2019HC WainwrightReiterated RatingHold$1.25High
11/5/2018HC WainwrightDowngradeBuy ➝ Neutral$3.00 ➝ $0.75High
10/12/2018HC WainwrightLower TargetBuy$7.00 ➝ $3.00Medium
10/12/2018JMP SecuritiesBoost TargetOutperform$4.00 ➝ $15.00High
10/12/2018Needham & Company LLCDowngradeBuy ➝ HoldHigh
10/10/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$10.00 ➝ $1.00High
8/13/2018HC WainwrightReiterated RatingBuy$7.00Low
5/7/2018CowenReiterated RatingBuy$10.00High
5/3/2018OppenheimerSet TargetBuy$5.00High
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Trevena logo
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
Read More

Today's Range

Now: $0.70
Low: $0.70
High: $0.87

50 Day Range

MA: $1.17
Low: $0.67
High: $1.90

52 Week Range

Now: $0.70
Low: $0.65
High: $15.28

Volume

450,107 shs

Average Volume

102,167 shs

Market Capitalization

$4.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Trevena?

The following Wall Street sell-side analysts have issued reports on Trevena in the last twelve months: HC Wainwright, and StockNews.com.
View the latest analyst ratings for TRVN.

What is the current price target for Trevena?

1 Wall Street analysts have set twelve-month price targets for Trevena in the last year. Their average twelve-month price target is $1.50, suggesting a possible upside of 79.7%. HC Wainwright has the highest price target set, predicting TRVN will reach $1.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.50 for Trevena in the next year.
View the latest price targets for TRVN.

What is the current consensus analyst rating for Trevena?

Trevena currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TRVN.

What other companies compete with Trevena?

Other companies that are similar to Trevena include Vallon Pharmaceuticals, Histogen, Timber Pharmaceuticals, AcelRx Pharmaceuticals and NeuroBo Pharmaceuticals. Learn More about companies similar to Trevena.

How do I contact Trevena's investor relations team?

Trevena's physical mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company's listed phone number is (610) 354-8840 and its investor relations email address is [email protected] The official website for Trevena is www.trevena.com. Learn More about contacing Trevena investor relations.